secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001104659-26-044093
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx raises ~$2.5M in registered direct offering plus up to $4.6M from warrants
--------------------------------------------------------------------------------

- Priced 825,085 shares (or pre-funded warrants) at $3.03/share for ~$2.5M gross proceeds.
- Concurrent private placement of 1,650,170 Series H warrants at $2.78/share, exercisable for 24 months.
- Potential additional gross proceeds of ~$4.6M if short-term warrants fully exercised on cash basis.
- Proceeds to be used for working capital and general corporate purposes.
- H.C. Wainwright & Co. acted as exclusive placement agent; fees 6.0% of gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/0001104659-26-044093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465926044093/tm2611957d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer